Suppr超能文献

趋化因子调控树突状细胞的抗原反应:第二部分——通过部分维持未成熟树突状细胞表型来调控抗原呈递给 T 淋巴细胞。

Chemokine programming dendritic cell antigen response: part II - programming antigen presentation to T lymphocytes by partially maintaining immature dendritic cell phenotype.

机构信息

Department of Bioengineering, University of Washington, Seattle, WA 98195, USA.

出版信息

Immunology. 2013 May;139(1):88-99. doi: 10.1111/imm.12059.

Abstract

In a companion article to this study,(1) the successful programming of a JAWSII dendritic cell (DC) line's antigen uptake and processing was demonstrated based on pre-treatment of DCs with a specific 'cocktail' of select chemokines. Chemokine pre-treatment modulated cytokine production before and after DC maturation [by lipopolysaccharide (LPS)]. After DC maturation, it induced an antigen uptake and processing capacity at levels 36% and 82% higher than in immature DCs, respectively. Such programming proffers a potential new approach to enhance vaccine efficiency. Unfortunately, simply enhancing antigen uptake does not guarantee the desired activation and proliferation of lymphocytes, e.g. CD4(+) T cells. In this study, phenotype changes and antigen presentation capacity of chemokine pre-treated murine bone marrow-derived DCs were examined in long-term co-culture with antigen-specific CD4(+) T cells to quantify how chemokine pre-treatment may impact the adaptive immune response. When a model antigen, ovalbumin (OVA), was added after intentional LPS maturation of chemokine-treated DCs, OVA-biased CD4(+) T-cell proliferation was initiated from ~ 100% more undivided naive T cells as compared to DCs treated only with LPS. Secretion of the cytokines interferon-γ, interleukin-1β, interleukin-2 and interleukin-10 in the CD4(+) T cell : DC co-culture (with or without chemokine pre-treatment) were essentially the same. Chemokine programming of DCs with a 7 : 3 ratio of CCL3 : CCL19 followed by LPS treatment maintained partial immature phenotypes of DCs, as indicated by surface marker (CD80 and CD86) expression over time. Results here and in our companion paper suggest that chemokine programming of DCs may provide a novel immunotherapy strategy to obviate the natural endocytosis limit of DC antigen uptake, thus potentially increasing DC-based vaccine efficiency.

摘要

在这项研究的一篇相关文章中,(1) 研究人员展示了 JAWSII 树突状细胞 (DC) 系成功进行抗原摄取和加工的编程,该编程基于 DC 预先用特定的“鸡尾酒”选择趋化因子处理。趋化因子预处理调节了 DC 成熟前后细胞因子的产生[脂多糖 (LPS)]。DC 成熟后,诱导抗原摄取和加工能力分别比未成熟 DC 高 36%和 82%。这种编程提供了一种增强疫苗效率的潜在新方法。不幸的是,仅仅增强抗原摄取并不能保证淋巴细胞(例如 CD4(+)T 细胞)的理想激活和增殖。在这项研究中,研究人员检查了趋化因子预处理的鼠骨髓来源的 DC 与抗原特异性 CD4(+)T 细胞长期共培养后的表型变化和抗原呈递能力,以量化趋化因子预处理如何影响适应性免疫反应。当在故意用 LPS 成熟趋化因子处理的 DC 后添加模型抗原卵清蛋白 (OVA) 时,与仅用 LPS 处理的 DC 相比,OVA 偏向的 CD4(+)T 细胞增殖从~100%更多未分裂的幼稚 T 细胞开始。在 CD4(+)T 细胞:DC 共培养物(无论是否进行趋化因子预处理)中,细胞因子干扰素-γ、白细胞介素-1β、白细胞介素-2 和白细胞介素-10 的分泌基本相同。用 CCL3:CCL19 的 7:3 比例对 DC 进行趋化因子编程,然后用 LPS 处理,可保持 DC 的部分不成熟表型,这表明随着时间的推移表面标志物(CD80 和 CD86)的表达。本文和我们的配套论文中的结果表明,趋化因子对 DC 的编程可能提供一种新的免疫治疗策略,以避免 DC 抗原摄取的自然内吞限制,从而提高基于 DC 的疫苗效率。

相似文献

4
Marina crystal minerals (MCM) activate human dendritic cells to induce CD4+ and CD8+ T cell responses in vitro.
Int J Immunopathol Pharmacol. 2018 Jan-Dec;32:2058738418797768. doi: 10.1177/2058738418797768.
7
Isoflavones, genistein and daidzein, regulate mucosal immune response by suppressing dendritic cell function.
PLoS One. 2012;7(10):e47979. doi: 10.1371/journal.pone.0047979. Epub 2012 Oct 22.
8
Epinephrine-primed murine bone marrow-derived dendritic cells facilitate production of IL-17A and IL-4 but not IFN-γ by CD4+ T cells.
Brain Behav Immun. 2010 Oct;24(7):1126-36. doi: 10.1016/j.bbi.2010.05.003. Epub 2010 May 31.
9
Lactoferrin modulation of BCG-infected dendritic cell functions.
Int Immunol. 2009 Oct;21(10):1185-97. doi: 10.1093/intimm/dxp084. Epub 2009 Aug 19.
10
Effect of T helper 1 (Th1)/Th2 cytokine on chemokine-induced dendritic cell functions.
Cell Immunol. 2006 Aug;242(2):72-9. doi: 10.1016/j.cellimm.2006.09.007. Epub 2006 Nov 13.

引用本文的文献

1
Design of Experiments to Achieve an Efficient Chitosan-Based DNA Vaccine Delivery System.
Pharmaceutics. 2021 Aug 31;13(9):1369. doi: 10.3390/pharmaceutics13091369.

本文引用的文献

2
Interleukin-2 production by dendritic cells and its immuno-regulatory functions.
Front Immunol. 2012 Jun 18;3:161. doi: 10.3389/fimmu.2012.00161. eCollection 2012.
3
5
T-cell activation and transplantation tolerance.
Transplant Rev (Orlando). 2012 Jul;26(3):212-22. doi: 10.1016/j.trre.2011.09.002. Epub 2011 Nov 8.
7
The impact of nanoparticle ligand density on dendritic-cell targeted vaccines.
Biomaterials. 2011 Apr;32(11):3094-105. doi: 10.1016/j.biomaterials.2010.12.054. Epub 2011 Jan 22.
8
Improvement of different vaccine delivery systems for cancer therapy.
Mol Cancer. 2011 Jan 7;10:3. doi: 10.1186/1476-4598-10-3.
10
Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation.
Blood. 2010 Sep 30;116(13):2277-85. doi: 10.1182/blood-2010-02-268425. Epub 2010 Jun 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验